End-of-day quote
Taipei Exchange
03:30:00 14/06/2024 am IST
|
5-day change
|
1st Jan Change
|
21.55
TWD
|
0.00%
|
|
+0.47%
|
-1.82%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
690.9
|
893.7
|
1,872
|
1,342
|
1,443
|
1,637
|
Enterprise Value (EV)
1 |
1,711
|
1,541
|
1,734
|
912.9
|
816.8
|
1,411
|
P/E ratio
|
13.8
x
|
14.7
x
|
34.9
x
|
24.3
x
|
23
x
|
21.5
x
|
Yield
|
6.7%
|
-
|
2.23%
|
2.78%
|
3.36%
|
4.19%
|
Capitalization / Revenue
|
0.53
x
|
0.8
x
|
1.5
x
|
1.42
x
|
1.42
x
|
1.44
x
|
EV / Revenue
|
1.31
x
|
1.39
x
|
1.39
x
|
0.97
x
|
0.8
x
|
1.24
x
|
EV / EBITDA
|
33.9
x
|
22.7
x
|
34.8
x
|
15.7
x
|
11.9
x
|
15.6
x
|
EV / FCF
|
-6.43
x
|
2.93
x
|
4.06
x
|
2.18
x
|
10.8
x
|
-3.99
x
|
FCF Yield
|
-15.6%
|
34.1%
|
24.6%
|
45.8%
|
9.24%
|
-25.1%
|
Price to Book
|
0.57
x
|
0.71
x
|
1.05
x
|
0.74
x
|
0.77
x
|
0.81
x
|
Nbr of stocks (in thousands)
|
44,574
|
44,574
|
74,574
|
74,574
|
74,574
|
74,574
|
Reference price
2 |
15.50
|
20.05
|
25.10
|
18.00
|
19.35
|
21.95
|
Announcement Date
|
28/03/19
|
06/03/20
|
29/03/21
|
25/03/22
|
25/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,302
|
1,112
|
1,251
|
945.7
|
1,018
|
1,140
|
EBITDA
1 |
50.46
|
67.94
|
49.82
|
58
|
68.84
|
90.27
|
EBIT
1 |
46.41
|
65.52
|
48.33
|
54.43
|
64.12
|
81.9
|
Operating Margin
|
3.57%
|
5.89%
|
3.86%
|
5.76%
|
6.3%
|
7.18%
|
Earnings before Tax (EBT)
1 |
46.34
|
74.65
|
62.72
|
68.12
|
79.5
|
95.5
|
Net income
1 |
50.28
|
60.63
|
47.25
|
55.3
|
62.62
|
76.53
|
Net margin
|
3.86%
|
5.45%
|
3.78%
|
5.85%
|
6.15%
|
6.71%
|
EPS
2 |
1.120
|
1.360
|
0.7200
|
0.7400
|
0.8397
|
1.020
|
Free Cash Flow
1 |
-266.2
|
525.4
|
427
|
418.2
|
75.49
|
-353.6
|
FCF margin
|
-20.45%
|
47.24%
|
34.13%
|
44.22%
|
7.42%
|
-31.02%
|
FCF Conversion (EBITDA)
|
-
|
773.33%
|
857.17%
|
721%
|
109.67%
|
-
|
FCF Conversion (Net income)
|
-
|
866.58%
|
903.81%
|
756.2%
|
120.56%
|
-
|
Dividend per Share
2 |
1.039
|
-
|
0.5602
|
0.5000
|
0.6500
|
0.9197
|
Announcement Date
|
28/03/19
|
06/03/20
|
29/03/21
|
25/03/22
|
25/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1,020
|
647
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
138
|
429
|
626
|
226
|
Leverage (Debt/EBITDA)
|
20.21
x
|
9.53
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-266
|
525
|
427
|
418
|
75.5
|
-354
|
ROE (net income / shareholders' equity)
|
4.44%
|
4.91%
|
3.11%
|
3.07%
|
3.38%
|
3.92%
|
ROA (Net income/ Total Assets)
|
0.58%
|
0.97%
|
0.78%
|
0.81%
|
0.85%
|
0.97%
|
Assets
1 |
8,703
|
6,270
|
6,027
|
6,858
|
7,368
|
7,900
|
Book Value Per Share
2 |
27.10
|
28.30
|
23.90
|
24.40
|
25.20
|
27.10
|
Cash Flow per Share
2 |
1.800
|
3.760
|
5.520
|
7.780
|
9.260
|
7.430
|
Capex
1 |
0.3
|
3.08
|
3.71
|
12.8
|
22.4
|
17.3
|
Capex / Sales
|
0.02%
|
0.28%
|
0.3%
|
1.36%
|
2.2%
|
1.52%
|
Announcement Date
|
28/03/19
|
06/03/20
|
29/03/21
|
25/03/22
|
25/03/23
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -1.82% | 49.61M | | +27.42% | 76.68B | | -0.60% | 24.41B | | +7.82% | 8.81B | | +10.46% | 8.48B | | -25.33% | 7.47B | | +15.02% | 5.21B | | +1.24% | 4.12B | | -8.45% | 3.86B | | -3.20% | 3.56B |
Pharmaceuticals Wholesale
|